annual-mental-health-2019-posters-abstracts

4 / 20

Find More Information @ March 2019 Conference Series LLC Ltd 43
conferenceseries LLC Ltd
6th World Congress on
Mental Health, Psychiatry and Wellbeing
March 20-21, 2019 | New York, USA
Detection of circulating
miRNA levels in large
cohort schizophrenia
Xu Qi
Peking Union Medical College,
China
Statement of the problem:
Schizophrenia is one of the
most common severe mental
disorders, with a lifetime risk of
1% in the population worldwide.
Over the years, the diagnosis
of schizophrenia has remained
symptom-based, relying mainly
on self-reports from patients,
mental state examination, and
clinical interviews, and lacking
objective laboratory tests. Such a
diagnostic strategy can sometimes
lead to misdiagnosis and has been
criticized widely. To remedy this
embarrassing state of affairs, a set
of biomarkers has been proposed
based on physical and biological
tests. In a currently finished
study, global plasma miRNAs
were profiled in a test cohort of
850 schizophrenia patients and
963 control subjects, using RNA
sequencing, TaqMan Low-Density
Array, and quantitative reverse
transcription polymerase chain
reaction (qRT-PCR) assays. The
captured miRNAs were then
validated by qRT-PCR assays in
an independent cohort of 623
schizophrenia patients, 654
control subjects. The global
plasma miRNA screening revealed
eight miRNAs that were up-
regulated in schizophrenia, as
revealed by both assay platforms.
The qRT-PCR analysis showed the
up-regulation of miR-17-5p and
miR-193a-3p in schizophrenia
but not in non-schizophrenia
disorders.
Conclusions: The up-regulation
of miR-17-5p and miR-193a-3p is
a state-independent biomarker
for schizophrenia, and these
two miRNAs could be used to
develop a diagnostic tool for
schizophrenia.
Biography
Xu Qi received her PhD from Peking Union
Medical College (PUMC) in 2004. Dr. Xu is
a Principal Investigator at Institute of Basic
Medical Sciences and Peking Union Medical
College (CAMS). In the past 20 years, Dr.
Xu leads translational research studies that
combine functional genomic and biochemical
approaches in pursuit of molecular
mechanisms, biomarkers, and potential drug
targets underlying neuropsychiatric disorders.
Dr. Xu published over 60 research articles as
corresponding author or first author, some
on high-ranking Journals e.g. Nature, Nature
Genetics, Nature Structural & Molecular
Biology, Molecular Psychiatry, American
Journal of Psychiatry, Journal of Experimental
Medicine, and Biological Psychiatry
INTERNATIONAL JOURNAL OF EMERGENCYMENTAL HEALTH AND HUMAN RESILIENCE 2019, VOLUME 21
DOI: 10.4172/1522-4821-C2-030
POSTER PRESENTATIONS